Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease

Neurobiology of Disease

Volumn 19, Issue 1-2, 2005, Pages 96-107

  Lastres Becker, Isabel ^a,d   Molina Holgado, Francisco ^b   Ramos, José A ^a   Mechoulam, Raphael ^c   Fernández Ruiz, Javier ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

6 Hydroxydopamine; Anti inflammatory effects; Antioxidant properties; Basal ganglia; Cannabinoids; Glial cells; Neurodegeneration; Neuroprotection; Parkinson's disease

Indexed keywords

CANNABINOID DERIVATIVE; OXIDOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; EVALUATION; FOREBRAIN; MALE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 17444370570     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2004.11.009     Document Type: Article

References (99)

1. I.B. Adams, and B.R. Martin Cannabis: pharmacology and toxicology in animals and humans Addiction 91 1996 1585 1614
2. T. Alexi, C.V. Borlongan, R.L. Faull, C.E. Williams, R.G. Clark, P.D. Gluckman, and P.E. Hughes Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's disease Prog. Neurobiol. 60 2000 409 470
3. C. Benito, E. Nuñez, R.M. Tolon, E.J. Carrier, A. Rabano, C.J. Hillard, and J. Romero Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains J. Neurosci. 23 2003 11136 11141
4. T. Bisogno, L. Hanus, L. De Petrocellis, S. Tchilibon, D.E. Ponde, I. Brandi, A.S. Moriello, J.B. Davis, R. Mechoulam, and V. Di Marzo Molecular targets for cannabidiol and its synthetic analogues: effects on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide Br. J. Pharmacol. 134 2001 845 852
5. D. Blum, S. Torch, N. Lamberg, M.-F. Nisson, A.-L. Benabid, L.R. Sadou, and J.-M. Verna Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease Prog. Neurobiol. 65 2001 135 172
6. J.M. Brotchie Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease Mov. Disord. 13 1998 871 876
7. J.M. Brotchie The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease Ann. Neurol. 47 2000 S105 S114
8. A. Brunet, S.R. Datta, and M.E. Greenberg Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway Curr. Opin. Neurobiol. 11 2001 297 305
9. M.A. Cambray-Deakin Cerebellar granule cells J. Cohen G. Wilkin Neural Cell Culture: A Practical Approach 1995 IRL Press Oxford, UK
10. A. Carlsson Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems J. Neural Transm. 109 2002 777 787
11. J. Carmichael, W.G. De Graff, A.F. Gazdar, J.D. Minna, and J.B. Mitchell Evaluation of the tetrazolium based semiautomated colorimetric assay: assessment of chemosensitivity testing Cancer Res. 47 1987 936 942
12. C.C. Chao, S. Hu, and P.K. Peterson Glia: the not so innocent bystanders J. NeuroVirol. 2 1996 234 239
13. Y. Chen, and J. Buck Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism J. Pharmacol. Exp. Ther. 293 2000 807 812
14. D. Daily, A. Barzilai, D. Offen, A. Kamsler, E. Melamed, and I. Ziv The involvement of p53 in dopamine-induced apoptosis of cerebellar granule neurons and leukemic cells overexpressing p53 Cell. Mol. Neurobiol. 19 1999 261 276
15. S. De Bernardo, S. Canals, M.J. Casarejos, E. Rodriguez-Martin, and M.A. Mena Glia-conditioned medium induces de novo synthesis of tyrosine hydroxylase and increases dopamine cell survival by differential signaling pathways J. Neurosci. Res. 73 2003 818 830
16. V. Di Marzo, M.P. Hill, T. Bisogno, A.R. Crossman, and J.M. Brotchie Enhanced levels of endocannabinoids in the globus pallidus are associated with a reduction of movement in an animal model of Parkinson's disease FASEB J. 14 2000 1432 1438
17. R.C. Dodel, Y. Du, K.R. Bales, Z. Ling, P.M. Carvey, and S.M. Paul Caspase-3-like proteases and 6-hydroxydopamine induced neuronal cell death Mol. Brain Res. 64 1999 141 148
18. B. Ferrer, N. Asbrock, S. Kathuria, D. Piomelli, and A. Giuffrida Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias Eur. J. Neurosci. 18 2003 1114 1607
19. S.H. Fox, B. Henry, M.P. Hill, A.R. Crossman, and J.M. Brotchie Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease Mov. Disord. 17 2002 1180 1187
20. E. Galea, D.L. Feinstein, and D.J. Reis Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures Proc. Natl. Acad. Sci. U. S. A. 89 1992 10945 10949
21. H.M. Gao, J. Jiang, B. Wilson, W. Zhang, J.S. Hong, and B. Liu Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease J. Neurochem. 81 2002 1285 1297
22. 1-tetrahydrocannabinol and other neutral cannabinoids from hashish J. Am. Chem. Soc. 93 1971 217 224
23. 9-tetrahydrocannabinol exposure did not alter dopamine transporter and tyrosine hydroxylase mRNA levels in midbrain dopaminergic neurons of adult male and female rats Neurotoxicol. Teratol. 20 1998 549 553
24. C.R. Gerfen The neostriatal mosaic: multiple levels of compartmental organization Trends Neurosci. 15 1992 133 139
25. Y. Gilgun-Sherki, E. Melamed, R. Mechoulam, and D. Offen The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats Pharmacol. Toxicol. 93 2003 66 70
26. T. Gomez Del Pulgar, M.L. De Ceballos, M. Guzman, and G. Velasco Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway J. Biol. Chem. 277 2002 36527 36533
27. S. González, J. Romero, R. de Miguel, I. Lastres-Becker, M.A. Villanua, A. Makriyannis, J.A. Ramos, and J.J. Fernández-Ruiz Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide Life Sci. 65 1999 327 336
28. R.I. Grundy The therapeutic potential of the cannabinoids in neuroprotection Expert Opin. Invest. Drugs 11 2002 1 10
29. R.I. Grundy, M. Rabuffetti, and M. Beltramo Cannabinoids and neuroprotection Mol. Neurobiol. 24 2001 29 52
30. P. Gubellini, B. Picconi, M. Bari, N. Battista, P. Calabresi, D. Centonze, G. Bernardi, A. Finazzi-Agrò, and M. Maccarrone Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission J. Neurosci. 22 2002 6900 6907
31. M. Guzmán, C. Sánchez, and I. Galve-Roperh Control of the cell survival/death decision by cannabinoids J. Mol. Med. 78 2001 613 625
32. 9-tetrahydrocannabinol are neuroprotective antioxidants Proc. Natl. Acad. Sci. U. S. A. 95 1998 8268 8273
33. A.J. Hampson, M. Grimaldi, M. Lolic, D. Wink, R. Rosenthal, and J. Axelrod Neuroprotective antioxidants from marijuana Ann. N. Y. Acad. Sci. 899 2000 274 282
34. M. Herkenham, A.B. Lynn, M.D. Little, L.S. Melvin, M.R. Johnson, D.R. de Costa, and K.C. Rice Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study J. Neurosci. 11 1991 563 583
35. M.L. Hernández, F. Berrendero, I. Suarez, L. Garcia-Gil, M. Cebeira, K. Mackie, J.A. Ramos, and J.J. Fernández-Ruiz Cannabinoid CB1 receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme Brain Res. 857 2000 56 65
36. E.C. Hirsch Glial cells and Parkinson's disease J. Neurol. 247 2000 II58 II62
37. E.C. Hirsch, S. Hunot, P. Damier, and B. Faucheux Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? W.C. Olanow P. Jenner Beyond the Decade of the Brain Neuroprotection in Parkinson's Disease vol. 3 1998 Wells Medical Ltd. Royal Tunbridge Wells, UK 227 237
38. M.J. Hurley, D.C. Mash, and P. Jenner Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain J. Neural Transm. 110 2003 1279 1288
39. S.I. Jaggar, F.S. Hasnie, S. Sellaturay, and A.S. Rice The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain Pain 76 1998 189 199
40. W.G. Kim, R.P. Mohney, B. Wilson, G.H. Jeohn, B. Liu, and J.S. Hong Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia J. Neurosci. 20 2000 6309 6316
41. R. Kumar, A.K. Agarwal, and P.K. Seth Free radical-generated neurotoxicity of 6-hydroxydopamine J. Neurochem. 64 1995 1703 1707
42. I. Lastres-Becker, M. Cebeira, M.L. de Ceballos, B.Y. Zeng, P. Jenner, J.A. Ramos, and J.J. Fernandez-Ruiz Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets Eur. J. Neurosci. 14 2001 1827 1832
43. I. Lastres-Becker, H.H. Hansen, F. Berrendero, R. De Miguel, A. Perez-Rosado, J. Manzanares, J.A. Ramos, and J.J. Fernandez-Ruiz Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease Synapse 44 2002 23 35
44. I. Lastres-Becker, N. Bizat, F. Boyer, P. Hantraye, J.J. Fernández-Ruiz, and E. Brouillet Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo NeuroReport 15 2004 2375 2379
45. M.L. López-Rodríguez, A. Viso, S. Ortega-Gutiérrez, C.J. Fowler, G. Tiger, E. de Lago, J. Fernández-Ruiz, and J.A. Ramos Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase J. Med. Chem. 46 2003 1512 1522
46. J. Lotharius, L.L. Dugan, and K.L. O'Malley Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons J. Neurosci. 19 1999 1284 1293
47. P. Mailleux, and J.J. Vanderhaeghen Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study J. Neurochem. 61 1993 1705 1712
48. A.M. Malfait, R. Gallily, P.F. Sumariwalla, A.S. Malik, E. Andreakos, R. Mechoulam, and M. Feldmann The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis Proc. Natl. Acad. Sci. 97 2000 9561 9566
49. Y.P. Maneuf, A.R. Crossman, and J.M. Brotchie The cannabinoid receptor agonist WIN55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease Exp. Neurol. 148 1997 265 270
50. 1 J. Neurochem. 80 2002 448 456
51. K.D. McCarthy, and J. de Vellis Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue J. Cell Biol. 85 1980 890 902
52. P.L. McGeer, K. Yasojima, and E.G. McGeer Inflammation in Parkinson's disease Adv. Neurol. 86 2001 83 89
53. R. Mechoulam, N. Lander, A. Breuer, and J. Zahalka Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative Tetrahedron: Asymmetry 1 1990 315 319
54. R. Mechoulam, A. Panikashvili, and E. Shohami Cannabinoids and brain injury: therapeutic implications Trends Mol. Med. 8 2002 58 61
55. R. Mechoulam, M. Spatz, and E. Shohami Endocannabinoids and neuroprotection Sci. STKE 2002 10.1126/stke.1292002re5
56. J.P. Meschler, A.C. Howlett, and B.K. Madras Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5, 6-tetrahydropyridine (MPTP)-treated non-human primates Psychopharmacology 156 2001 79 85
57. E. Mezey, Z.E. Toth, D.N. Cortright, M.K. Arzubi, J.E. Krause, R. Elde, A. Guo, P.M. Blumberg, and A. Szallasi Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human Proc. Natl. Acad. Sci. U. S. A. 97 2000 3655 3660
58. L. Minghetti, and G. Levi Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide Prog. Neurobiol. 54 1998 99 125
59. M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients Neurosci. Lett. 165 1994 208 210
60. F. Molina-Holgado, A. Lledo, and C. Guaza Evidence for cyclooxygenase activation by nitric oxide in astrocytes Glia 15 1995 167 172
61. F. Molina-Holgado, E. Pinteaux, J.D. Moore, E. Molina-Holgado, C. Guaza, R.M. Gibson, and N.J. Rothwell Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia J. Neurosci. 23 2003 6470 6474
62. F. Molina-Holgado, E. Pinteaux, L. Heenan, J.D. Moore, N.J. Rothwell, and R.M. Gibson Neuroprotective effects of the synthetic cannabinoid HU-210 in cortical neurons are mediated by phosphatidylinositol/Akt signaling Mol. Cell. Neurosci. 2004 (in press)
63. B. Moosmann, and C. Behl Antioxidants as treatment for neurodegenerative disorders Expert Opin. Invest. Drugs 11 2002 1407 1435
64. T. Nagatsu, K. Oka, and T. Kato Highly sensitive assay for tyrosine-hydroxylase activity by high-performance liquid chromatography J. Chromatogr. 163 1979 247 252
65. T. Nagatsu, M. Mogi, H. Ichinose, and A. Togari Changes in cytokines and neurotrophins in Parkinson's disease J. Neural Transm., Suppl. 60 2000 277 290
66. T. Nagayama, A.D. Sinor, R.P. Simon, J. Chen, S.H. Graham, K.L. Jin, and D.A. Greenberg Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures J. Neurosci. 19 1999 2987 2995
67. H. Nawa, H. Kotani, and S. Nakanishi Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing Nature 312 1984 729 734
68. D. Offen, Y. Sherki, E. Melamed, M. Fridkin, D.E. Brenneman, and I. Gozes Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease Brain Res. 854 2000 257 262
69. M. Palkovits, and J. Brownstein Maps and Guide to Microdissection of the Rat Brain 1988 Elsevier
70. D. Panikashvili, C. Simeonidou, S. Ben-Shabat, L. Hanus, A. Breuer, R. Mechoulam, and E. Shohami An endogenous cannabinoid (2-AG) is neuroprotective after brain injury Nature 413 2001 527 531
71. 1 cannabinoid receptor knock-out mice J. Neurosci. 22 2002 9771 9775
72. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 1986 Academic Press London
73. 2 receptors Pharmacol. Ther. 74 1997 129 180
74. C. Raman, S.D. McAllister, G. Rizvi, S.G. Patel, D.H. Moore, and M.E. Abood Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid Amyotrophic Lateral. Scler., Other Mot. Neuron Disord. 5 2004 33 39
75. J.D. Richardson, S. Kilo, and K.M. Hargreaves Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors Pain 75 1998 111 119
76. R.L. Rodnitzky Can calcium antagonists provide a neuroprotective effect in Parkinson's disease? Drugs 57 1999 845 849
77. J. Romero, R. de Miguel, E. García-Palomero, J.J. Fernández-Ruiz, and J.A. Ramos Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function Brain Res. 694 1995 223 232
78. J. Romero, F. Berrendero, A. Pérez-Rosado, J. Manzanares, A. Rojo, J.J. Fernández-Ruiz, J.G. de Yébenes, and J.A. Ramos Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen Life Sci. 66 2000 485 494
79. J. Romero, I. Lastres-Becker, R. de Miguel, F. Berrendero, J. Ramos, and J. Fernández-Ruiz The endogenous cannabinoid system and the basal ganglia. Biochemical, pharmacological, and therapeutic aspects Pharmacol. Ther. 95 2002 137 152
80. T. Rubino, P. Massi, G. Patrini, I. Venier, G. Giagnoni, and D. Parolaro Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study NeuroReport 5 1994 2493 2496
81. M.C. Sañudo-Peña, S.L. Patrick, S. Khen, R.L. Patrick, K. Tsou, and J.M. Walker Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease Neurosci. Lett. 248 1998 171 174
82. K.D. Sethi Clinical aspects of Parkinson disease Curr. Opin. Neurol. 15 2002 457 460
83. M. Shen, and S.A. Thayer Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity Mol. Pharmacol. 54 1998 459 462
84. T.B. Sherer, R. Betarbet, and J.T. Greenamyre Pathogenesis of Parkinson's disease Curr. Opin. Invest. Drugs 2 2001 657 662
85. K.A. Sieradzan, S.H. Fox, M. Hill, J.P. Dick, A.R. Crossman, and J.M. Brotchie Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study Neurology 57 2001 2108 2111
86. M.A. Silverdale, S. McGuire, A. McInnes, A.R. Crossman, and J.M. Brotchie Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease Exp. Neurol. 169 2001 400 406
87. M.L. Simmons, and S. Murphy Induction of nitric oxide synthase in glial cells J. Neurochem. 59 1992 897 905
88. A.D. Sinor, S.M. Irvin, and D.A. Greenberg Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats Neurosci. Lett. 278 2000 157 160
89. S.R. Smith, C. Terminelli, and G. Denhardt Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice J. Pharmacol. Exp. Ther. 293 2000 136 150
90. R. Tintner, and J. Jankovic Treatment options for Parkinson's disease Curr. Opin. Neurol. 15 2002 467 476
91. F.J. Vajda Neuroprotection and neurodegenerative disease J. Clin. Neurosci. 9 2002 4 8
92. 9- tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity J. Neurosci. 21 2001 6475 6579
93. M. van der Stelt, W.B. Veldhuis, G.W. van Haaften, F. Fezza, T. Bisogno, P.R. Bär, G.A. Veldink, J.F. Vliegenthart, V. Di Marzo, and K. Nicolay Exogenous anandamide protects rat brain against acute neuronal injury in vivo J. Neurosci. 21 2001 8765 8771
94. Y. Waksman, J.M. Olson, S.J. Carlisle, and G.A. Cabral The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells J. Pharmacol. Exp. Ther. 288 1999 1357 1366
95. L. Walter, and N. Stella Cannabinoids and neuroinflammation Br. J. Pharmacol. 141 2004 775 785
96. L. Walter, A. Franklin, A. Witting, C. Wade, Y. Xie, G. Kunos, K. Mackie, and N. Stella Nonpsychotropic cannabinoid receptors regulate microglial cell migration J. Neurosci. 23 2003 1398 1405
97. W.S. Young, T.I. Bonner, and M.R. Brann Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain Proc. Natl. Acad. Sci. U. S. A. 83 1986 9827 9831
98. M. Zalish, and V. Lavie Dexanabinol (HU-211) has a beneficial effect on axonal sprouting and survival after rat optic nerve crush injury Vision Res. 43 2003 237 242
99. B.-Y. Zeng, B. Dass, A. Owen, S. Rose, C. Cannizzaro, B.C. Tel, and P. Jenner Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats Neurosci. Lett. 276 1999 71 74